🇺🇸 FDA

Drug profile · INN

loncastuximab tesirine-lpyl

ZYNLONTA

approved
US status
approved
Patents linked
0
News articles
0

Quick answer

loncastuximab tesirine-lpyl (ZYNLONTA) is an FDA-listed pharmaceutical active ingredient. Associated with ADC Therapeutics SA. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN loncastuximab tesirine-lpyl
Brand ZYNLONTA
Route INJECTION
Formulation INJECTABLE
Originator ADC Therapeutics SA

Frequently asked questions

What is loncastuximab tesirine-lpyl?

loncastuximab tesirine-lpyl (ZYNLONTA) is an FDA-listed pharmaceutical active ingredient. Associated with ADC Therapeutics SA. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for loncastuximab tesirine-lpyl?

ZYNLONTA is a marketed brand name for loncastuximab tesirine-lpyl. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of loncastuximab tesirine-lpyl?

loncastuximab tesirine-lpyl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.